试点规模生产一种高效和稳定的单糖基化流感病毒分裂疫苗
Chia-Ying Wu1, Shao-En Kao1, Yung-Chieh Tseng1
1RuenHuei Biopharmaceuticals Inc., Taipei, Taiwan.
Vaccine
|April 6, 2024
概括
一种新的单糖基化流感病毒疫苗 (IVR-190mg) 在大规模生产和对H1N1变种的广泛保护方面显示出有希望的结果. 这种新型疫苗平台在临床前研究中证明了安全性和免疫性,为临床试验铺平了道路.
科学领域:
- 病毒学和免疫学 病毒学和免疫学
- 疫苗开发和制造 疫苗开发和制造
背景情况:
- 每年的流感流行和不可预测的疫情需要有效的疫苗来对抗新兴变种.
- 之前的研究表明,单糖化流感疫苗比完全糖化疫苗提供更广泛的保护.
- 单糖系疫苗的临床可扩展性和稳定性仍未得到解决.
研究的目的:
- 开发一种可扩展且具有成本效益的制造工艺,用于从A/Brisbane/02/2018 (IVR-190) 菌株制造的单糖化分裂病毒疫苗 (IVR-190mg).
- 评估IVR-190mg疫苗的分批一致性,规格,稳定性和安全性.
- 评估IVR-190mg在临床前研究中对H1N1变种的免疫性和保护效果.
主要方法:
- 试点规模生产IVR-190mg,使用针对注射剂量,基森度和EndoH治疗的优化参数.
- 工程批量运行以验证一致性;建立疫苗规格.
- 在子中进行稳定性分析和符合GLP的动物毒理学研究;针对免疫性进行血清学测定.
主要成果:
- 成功开发了一种强大且具有成本效益的IVR-190mg制造平台.
- 该疫苗表现出分批一致性,符合常规疫苗规格,并显示出有利的稳定性概况.
- 毒理学研究没有发现系统性毒性;血清学数据证实了高免疫性和对H1N1病毒的广泛交叉菌株保护.
结论:
- 单糖化分裂病毒疫苗IVR-190mg是安全的,免疫性,并表现出广泛的保护潜力对H1N1变种.
- 开发的制造工艺支持试点规模的生产,表明对临床需求的可行性.
- IVR-190mg显示出作为一种安全有效的针对各种H1N1菌株的疫苗的巨大潜力,需要进一步的临床研究.
相关概念视频
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...